Keryx Biopharmaceuticals Company Description
Drugs are a life-or-death business for Keryx Biopharmaceuticals. The company specializes in developing treatments for life-threatening ailments, such as cancer and kidney disease. Its lead candidate is Zerenex, a compound that may reduce high phosphate levels in patients with end-stage renal disease. The company is also developing KRX-0401 (also known as perifosine) to fight renal cell carcinoma and other cancers. Keryx suffered a major blow in 2008 when its previous lead candidate Sulonex failed in a pivotal clinical trial; the drug had been intended to treat diabetic nephropathy, a diabetes-related kidney disease.
View the Comprehensive Company Description for Keryx Biopharmaceuticals
The Company Description provides a historical perspective of Keryx Biopharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Keryx Biopharmaceuticals's evolution in the marketplace.
